Objective: Autologous vein is the conduit of choice for small artery reconstruction. Despite excellent patency, these conduits undergo remodeling over time. The purpose of this study was to identify temporal gene expression in vein grafts versus control veins through microarray analysis. Method: Cephalic vein grafts (n ‫؍‬ 12) were used to bypass femoral arteries in canines. Vein grafts were harvested after 1, 7, 14, and 30 days. Normal contralateral cephalic vein served as control. Total RNA was isolated; its quantity and quality were confirmed with spectrophotometry and gel electrophoresis. Affymetrix U133A GeneChips, comprising approximately 15,000 genes, were used to analyze differential gene expression at each time point. Statistical analysis was performed with Affymetrix and dChip software to identify consistently upregulated and downregulated genes. Real-time, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to validate microarray data. Results: Statistical analysis revealed that 49 genes were consistently upregulated and 31 genes were consistently downregulated in all three animals at various time points. qRT-PCR to quantitatively assess messenger RNA expression was performed on specific genes to validate the microarray data. Immunohistochemistry to qualitatively assess protein expression was used for further validation. Hierarchical clustering with dChip identified additional genes with similar temporal or functional expression patterns. Conclusions: This is the first study to use microarray analysis with confirmatory qRT-PCR to identify altered genes after vein bypass grafting. Oligonucleotide microarrays and hierarchical clustering are powerful tools to generate hypotheses as the basis for additional research on gene expression in vein graft remodeling. Ultimately, identification of a temporal sequence of differential gene expression may provide insights not preferred into the molecular mechanisms of vein graft remodeling, but also into the pathways leading to intimal hyperplasia. (J Vasc Surg 2004;39:645-54.)
Autologous vein is the only conduit for small artery reconstruction (Ͻ5 mm), on the basis of short-term and long-term patency results. 1 Despite patency superior to that with prosthetic conduits, vein grafts also undergo changes that may lead to delayed failure. 2, 3 This failure results from surgical trauma during vein harvesting and subsequent exposure of the vein to new hemodynamic forces in the arterial circulation. 4, 5 Vein grafts undergo remodeling changes similar to intimal hyperplasia, that is, vascular smooth muscle cell (VSMC) migration and proliferation, with secondary extracellular matrix production. This remodeling, or "arterialization," causes vein grafts to thicken with neointima, and can lead to recurrent stenosis at any point along the conduit.
The mechanism of vein graft failure is unclear, but altered gene regulation translates into altered anatomy.
Although various studies have identified individual genes with altered expression in "arterialized" veins, 6, 7 there is little understanding regarding temporal upregulation or downregulation of these genes. Microarrays represent a new technology to screen samples for thousands of genes at once, compared with older methods that tediously look at single genes and gene products, such as differential display and Western blot analysis. Recent investigations identified temporal genetic expression in animal models of prosthetic arterial bypass grafting. 8, 9 A few in vitro studies used microarrays to examine shear-stressed Human Umbilical Vein Endothelial Cells or mechanically induced VSMCs. 10, 11 However, this is the first in vivo study to evaluate differential gene expression in arterialized vein grafts by means of oligonucleotide microarray analysis.
On the basis of vein graft failure patterns, the hypotheses of this study were that vein bypass grafting causes immediate gene alteration in the graft wall and anastomoses; and that altered gene transcription into mRNA, and translation into protein, are the initial events in vein graft remodeling, and provide insights into molecular mechanisms of vein graft intimal hyperplasia. Certain changes are unavoidable on the basis of the inherent nature of surgical removal and reimplantation of veins, but identification of altered gene expression may provide new targets for intervention.
MATERIAL AND METHOD
Twelve canines (25 kg) were used for the study after institutional review board approval. Care complied with the Guide for the Care and Use of Laboratory Animals. Procedure. The model was a unilateral reversed cephalic vein to femoral artery interposition graft, as described. 12, 13 On the basis of previous data for prosthetic arterial grafting from this laboratory as well as related studies from other laboratories, animals were designated for vein graft harvesting at 1, 7, 14, or 30 days (n ϭ 3 at each time point). With the animal under general anesthesia, the left cephalic vein was lightly distended with saline solution (containing heparin and papaverine) and placed into culture media, as described. 14 After heparinization (100 U/kg), end-to-side anastomoses were created with 6-0 polypropylene (Prolene) sutures. The intervening right femoral artery was transected, establishing a functional end-to-end anastomosis. Protamine sulfate (0.3 mg/kg) was given. This model mimics clinical protocols for distal pedal and coronary artery reconstruction.
Harvesting was performed with the animal under general anesthesia. At the same time as graft harvest, the right cephalic vein was harvested and stored as described above, to serve as control tissue for the vein graft from the same animal. The vein graft was ligated immediately proximal to both anastomoses to exclude sutures and arterial tissue. The graft was flushed with saline solution; mid-portions of vein graft and control vein were placed into formalin for histologic analysis and immunohistochemistry. Remaining portions were immediately placed into RNAlater (Qiagen, Valencia, Calif) and stored at Ϫ20°C until RNA isolation. All bypass grafts were patent at harvest.
RNA isolation. Samples were rotor-homogenized and treated with proteinase K (Qiagen). Total RNA was extracted with RNeasy Midi Kits (Qiagen). RNA quantity was confirmed with spectrophotometry, and quality was confirmed with Millennium Markers (Ambion, Austin, Tex) on a denaturing agarose gel (Sigma, St Louis, Mo). Although control veins yielded relatively less total RNA than vein grafts did, absolute yields were sufficient for microarrays and real-time, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). No pooling of RNA from different samples was necessary.
Microarray analysis. Total RNA was prepared for Affymetrix U133A GeneChips (Santa Clara, Calif) at our Gene Array Technology Center. Complementary DNA was synthesized from total RNA (GeneChip Sample Cleanup Modules; Qiagen), a transcription reaction (Enzo BioArray High Yield RNA Transcript Labeling Kit, Farmingdale, NY) generated biotin-labeled cRNA. cRNA was fragmented and hybridized to the GeneChip. One batch of GeneChips was used at 1 and 7 days, and another batch was used at 14 and 30 days.
Affymetrix MAS 5.0 was used for statistical gene expression analysis to compare vein graft with control vein from the same animal. A gene was upregulated in vein graft, compared with control vein, if that gene was "PRESENT" in vein graft (qualitative detection of a particular transcript); was "INCREASED" in vein graft (qualitative comparison of transcript signal using control array as baseline); and had "SIGNAL LOG RATIO" of ϩ1.0 or greater, corresponding to "FOLD-CHANGE" of ϩ2.0 or greater (quantitative measure of relative change in transcript abundance). A gene was downregulated if that gene was "PRESENT" in control vein; was "DECREASED" in vein graft; and had "SIGNAL LOG RATIO" of Ϫ1.0 or less, corresponding to "FOLD-CHANGE" of Ϫ2.0 or less. To ensure that genes were not discovered by random chance within individual samples, genes had to satisfy the criteria in all three animals at a time point. dChip 1.2, a statistical program to analyze oligonucleotide microarrays, 15 was also used to screen for differentially expressed genes and to perform hierarchical clustering of the samples. RNA was compared between vein graft and control vein from the same animal; samples were simultaneously analyzed for 18S RNA as standardization. Reaction triplicates included 12.5 L SYBR Green Master Mix, 1.25 L primers (5 mol/L each of forward and reverse primers), 10.125 L of nuclease-free water, 1 L of RNA (1 g/ mL), and 0.125 L of MMLV-RT. Experiments included negative reverse transcription controls and negative template controls to monitor contamination. The ABI PRISM 7700 Sequence Detection System conditions were as follows: stage 1 (reverse transcription), 30 minutes (48°C); stage 2 (reverse transcriptase inactivation), 10 minutes (95°C); stage 3 (denaturation, then annealing/extension), 15 seconds (95°C) and 1 minute (60°C), for 40 cycles. Histologic analysis and immunohistochemistry. Mid-portions of each vein graft and control vein were processed through ethanol and embedded in paraffin. Sixmicrometer sections were cut, and stained with hematoxylineosin. For immunohistochemistry, 6-m sections were deparaffinized in xylene, and rehydrated. Heated citrate buffer antigen retrieval was performed when necessary. Sections were treated with 3% hydrogen peroxide. Nonserum protein blocking was followed by incubation over-night with primary antibody. Sections were incubated with biotinylated secondary antibody, streptavidin-peroxidase, and DAB (3,3Ј-diaminobenzidine)-chromagen, then counterstained with hematoxylin. Positive and negative controls were used.
The antibodies and dilutions used were ␣-smooth muscle actin (1:25; DAKO, Carpinteria, Calif), Ki-67 (1:150; DAKO), VEGF (1:400; Santa Cruz Biotechnology, Santa Cruz, Calif), and HIF-1␣ (1:150; Santa Cruz Biotechnology). The kits used were DAKO LSABϩ Kit, peroxidase, and DAKO Animal Research Kit, peroxidase.
RESULTS

Microarray analysis.
Microarray data are available at http:// home. caregroup. org/ templatesnew/ departments/ BID/vonliebig/uploaded_documents/kalishveinbypassdata. htm. Affymetrix U133A GeneChips probe for approximately 15,000 known genes (22,283 probe sets). Samples achieved 18% to 26% hybridization with GeneChips (mean, 22.9% Ϯ 2.4% ϭ 3435 Ϯ 360 genes [5102 Ϯ 535 probe sets]). On the basis of statistical standards endorsed in bioinformatics research, comparisons were made between vein graft and control vein from the same animal. At all four time points combined (with consistent upregulation or downregulation required in all three animals at a given time point), 49 genes were upregulated and 31 genes were downregulated (Tables I, II) . Numbers reflect average gene fold changes in vein graft compared with control vein in all three animals. Consistent upregulation or downregulation of a gene in three animals facilitated statistical significance. dChip 1.2 was used to analyze GeneChip output and compare gene expression at each time point. Hierarchical clustering revealed that control veins clustered together and vein grafts clustered together within each GeneChip batch (Fig 1) . Individual time points subclustered, with the exception of vein graft sample 07h1, owing to 8% outliers. The clustering algorithm is as follows: distance between two genes is defined as 1 Ϫ r, where r is the correlation coefficient between the standardized expression values of two genes. Two closest genes are merged into a supergene and connected by branches, with length representing distance. The expression value of this supergene is the average of standardized expression values of the two genes (centroid linkage). The next pair of genes (supergene) with the smallest distance is merged, and the process is repeated to merge all genes. 15 qRT-PCR. To validate microarray data, qRT-PCR was performed to assess RNA expression level accuracy. Mathematically normalizing HIF-1␣ results at 1 day with the standardization gene 18S revealed 2.5-fold upregulation of HIF-1␣ in vein graft versus control vein (Fig 2, A  and B ), confirming the microarray data. At 7 days HIF-1␣ had returned to baseline levels when normalized to 18S (Fig 2, C and D) . Similar results were obtained at 14 and 30 days (graphs not shown). Confirmatory qRT-PCR was similarly performed for VEGF and Smoothelin; results at each time point correlated with microarray data (graphs not shown).
Histologic analysis. Because vein grafts can fail at any place along the conduit, sections were taken from the mid-portion, where minimal trauma from manipulation would have occurred. Anastomoses were excluded because of this increased trauma inherent in the operation. It was believed that certain anastomotic genes might be absent from the remaining bypass graft but that all genes from minimally traumatized areas would be present at anastomoses. Control vein had an intact endothelial cell layer before implantation (Fig 3, A) . After 1 day there were migrating neutrophils and a dense layer of endothelial cells or VSMCs. After 7 days (Fig 3, B) there was a distinct layer of luminal intimal hyperplasia. After 14 days (Fig 3, C) there was medial hypertrophy and a layer of intimal hyperplasia. After 30 days (Fig 3, D) there was increased medial hypertrophy accompanied by extracellular matrix deposition.
Immunohistochemistry. Because of its relation to HIF-1␣, the other index gene used to validate the microarray was VEGF. VEGF antibody qualitatively demonstrated increased protein expression in vein grafts at day 1 compared with vein grafts at 7, 14, and 30 days (Fig 4, A-C; 14-day data not shown). Human placenta served as positive control, and appropriate negative controls were used. Ki-67 was used early, at 1 and 7 days, to identify cell proliferation (Fig 4, D and E) . ␣-Smooth muscle actin identified VSMCs (Fig 4, F-H) .
DISCUSSION
Vein bypass grafting causes remodeling changes similar to those of intimal hyperplasia. 5 Early changes initiate a sequence of genetic events in the vein graft wall and anastomoses; however, this genetic cascade has not been elucidated. This is the first study to use microarray analysis to identify a time line of genetic expression in an in vivo model of vein bypass grafting and to validate microarray results with qRT-PCR and immunohistochemistry. This study analyzed paired specimens from the same animal. Three animals were used at each time point, and four time points comprised the time line. Tables I and II suggest HIF-1␣ and VEGF were upregulated in vein grafts after 1 day, and returned to baseline levels thereafter. These genes were chosen as the index genes to validate microarray results, because they have been studied extensively in intimal hyperplasia. When a vein is used as an arterial conduit, physiologic and morphologic changes occur, including endothelial cell loss and recovery, wall thickening, and development of a variable layer of neointima. 6 When a vein is removed from its natural position and grafted, it suffers hypoxic stress. Hypoxia induces VEGF expression in both endothelial cells and VSMCs. 16, 17 This hypoxia most likely accounts for upregulation of HIF-1␣ and VEGF at 1 day. Exogenous VEGF increases reendothelialization after balloon catheter denudation injury. 18 Thus it is possible that VEGF is induced early, when the endothelial cells are partially lost, to promote reendothelialization. Similarly, VEGF may have returned to baseline by 7 days, either because endothelial cells have repopulated or simply because normoxic conditions have been restored.
Intimal hyperplasia leads to production of extracellular matrix, which incorporates collagens. 19 In this study certain collagens were downregulated at 1 day and subsequently became upregulated, including collagen type I (␣2) and procollagen-␣1 (type III). Variably upregulated collagens included collagen types I, III, IV, and XI, and procollagen type I. Collagens were also discovered by Geary et al 9 at 30 days. These data support sequential gene regulation dictated by changes in the adaptive and healing responses of the vein graft wall. In addition to collagens, seven additional genes were upregulated at more than one time point. Myristoylated alanine-rich protein kinase C substrate is the most prominent cellular substrate for protein kinase C. The protein binds calmodulin, actin, and synapsin, and also helps regulate endothelial cell proliferation. 20 Cyclin-dependent kinase regulatory subunit (CDC28) coordinates regulation of cellular proliferation and migration. 21 Versican connects cells with extracellular matrix, in addition to its regulatory role during cell migration and proliferation. 22 Seven additional genes were downregulated at more than one time point. Smoothelin is a marker of mature, contractile VSMCs. 23 Zinc finger proteins are transcription factors for other genes, including non-muscle myosin heavy chain B, which is a marker of phenotypically modulated smooth muscle cells. 24 RNA binding protein gene modulates the biologic processes of RNA processing, transport, and translation. 25 The analysis performed with dChip facilitated hierarchical clustering of the data. The principle of hierarchical clustering is that coregulated genes with similar patterns of expression are more likely to be involved in the same biologic pathway. Before drawing conclusions, however, each related gene requires the same stringent validation as used in this study. As noted, one GeneChip batch was used at days 1 and 7, and a different batch was used at 14 and 30 days. The ensuing "batch effect" gives the appearance of altered gene expression in control veins, but the altered expression similarly extends to the vein grafts and thus does not influence comparative results. The two main batches form two main sample clusters (Fig 1) . Within the main sample clusters, vein grafts clustered together and control veins clustered together. The subclustering of individual time points within each batch emphasized the reproducibility of this experiment. Overall, the importance of hierarchical clustering was to enable visualization of sample clustering and to generate hypotheses to guide future research into pathways of related genes.
A potential critique of this work is against creating a time line of genetic expression for vein graft intimal hyperplasia on the basis of three animals at each of four time points. However, the model is justified, given the strict criteria to judge gene "significance," as well as repetition within three biologically different samples. Statistical standards for claiming significance (fold-changes Ͼϩ2.0 or ϽϪ2.0) were adopted from other bioinformatics studies. 11, 26 Numerous studies with Affymetrix GeneChips revealed less than 2% rates of gene discovery due to array noise or chance, 27 and performing biologic replicates decreases this rate. 28 Even if there is a 5% chance of a gene being significantly regulated in one dog (higher than the accepted rate of Ͻ2%), the chance that it is significant in three dogs is 5% ϫ 5% ϫ 5% ϭ 0.0125%. Therefore, from approximately 15,000 genes (22, 283 probe sets) this would still equal only 1.88 genes (2.78 probe sets) due to noise or chance, representing a false discovery rate of 3.8% of the 49 upregulated genes and 6.0% of the 31 downregulated genes. False discovery rate calculated with dChip averaged 1.58% (1.4%, 3.0%, 0.6%, and 1.3% at each time point). The false discovery rate was determined with statistical analysis of 50 permutations of control and experimental data at each time point. These statistical algorithms lend power to the contention that nearly all 49 upregulated genes and nearly all 31 downregulated genes are not due to array noise or chance.
A debate in microarray papers regards cDNA versus oligonucleotide arrays. The U133A GeneChip, an oligonucleotide microarray, contains the most current and comprehensive list of genes to date. It uses multiple probe sets for each gene, including perfect matches and a mismatch probe set, to increase the statistical certainty that a gene deemed significant is not an error due to chance. Overall, as espoused by Li et al 29 from studying neuroblastoma cell lines, oligonucleotide arrays are more reliable for evaluating gene expression than cDNA arrays.
Geary et al 9 examined 30-day gene expression in monkey models of prosthetic arterial grafting to profile VSMC populations. The media from native aorta and vena cava, and neointima stripped from expandable polytetrafluoroethylene grafts were placed onto cDNA arrays to generate lists of regulated genes. Hilker et al 30 used cDNA arrays, but with only 91 genes, to examine aortocoronary bypass graft stenosis. Failed grafts (mean, 94.1 months) were compared with saphenous veins used for repeat grafts; six genes achieved twofold upregulation in at least three of five samples from human beings. Although many of the genes of Geary et al and Hilker et al are similar to those discovered here, our vein graft model seeks to answer different questions than prosthetic grafting or failed vein grafts, and further analysis is necessary before drawing conclusions about similar genes.
Nevertheless, Geary et al 9 and others 8, 31 prove that human array technology can be used to adequately study gene expression in various species. The canine model of vascular grafting has long been established as the model most similar to human beings with regard to failure pattern and healing mode. 32 Although canine arrays are not currently available, genes are conserved across species, and the number of known canine genes homologous to the human genome increases as the canine genome is mapped. 33 Canine tissue on human arrays is justified with independent validation of genes, as with qRT-PCR or immunohistochemistry. Although decreased hybridization of canine tissue to human arrays probably caused omission of some important genes, those genes that were discovered still provide an important foundation for vein graft intimal hyperplasia genetics.
Despite this overall justification, certain genes previously associated with models of intimal hyperplasia are noticeably absent from the microarray data. These include basic fibroblast growth factor, angiotensinogen, plateletderived growth factor A, transforming growth factor-␤, osteopontin, and elastin. Whether these differences are due to species variability or statistical selection criteria will need to be investigated. In addition, genes associated with vein graft remodeling are presumably not identical to genes expressed after injury models and prosthetic arterial grafting.
Although alternative models exist to study vein bypass grafting, none mimics human clinical procedures as well as this canine model. Mouse and rat models do not represent the natural progression of vein graft intimal hyperplasia, because these wire and balloon injury models more closely resemble clinical procedures of angioplasty or stenting. Monkeys are an option, but similar problems arise with non-human tissue on human arrays. Even human tissue placed on human arrays suffers hybridization ineffi- ciency, with rates in the literature ranging between 30% and 40%.
To gain more insight into gene localization, laser capture microdissection (LCM) may be used in future studies. LCM is a new tool for studying gene expression, and expands on current localization methods of immunohistochemistry or in situ hybridization. The technique enables microscopic visualization and isolation of selected cell populations from tissue sections. With LCM, areas of vein wall media can be isolated and compared with isolated areas of neointima, and RNA can be extracted from individual cell populations for qRT-PCR.
In conclusion, microarray analysis is not an end in and of itself, but serves as a platform to generate and test multiple hypotheses. The power of microarray technology and hierarchical clustering is the ability to facilitate simultaneous assessment of the constellations of genetic expression and to help identify patterns that might otherwise not have been discovered through searches of individual genes. To our knowledge, this is the first study to use microarray analysis to identify upregulated or downregulated genes after vein bypass grafting and to validate the microarray results with qRT-PCR and immunohistochemistry. Creation of a time line of differential gene expression for vein graft remodeling can provide new insights into the mechanisms of neointima formation, and may ultimately reveal targets for therapeutic intervention.
